Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Immune biology of glioma associated macrophages and microglia: Functional and therapeutic implications.

Wei J, Chen P, Gupta P, Ott M, Zamler D, Kassab C, Bhat KP, Curran MA, de Groot JF, Heimberger AB.

Neuro Oncol. 2019 Nov 3. pii: noz212. doi: 10.1093/neuonc/noz212. [Epub ahead of print]

PMID:
31679017
2.

The dystroglycan receptor maintains glioma stem cells in the vascular niche.

Day BW, Lathia JD, Bruce ZC, D'Souza RCJ, Baumgartner U, Ensbey KS, Lim YC, Stringer BW, Akgül S, Offenhäuser C, Li Y, Jamieson PR, Smith FM, Jurd CLR, Robertson T, Inglis PL, Lwin Z, Jeffree RL, Johns TG, Bhat KPL, Rich JN, Campbell KP, Boyd AW.

Acta Neuropathol. 2019 Dec;138(6):1033-1052. doi: 10.1007/s00401-019-02069-x. Epub 2019 Aug 28.

3.

Phenotypic Plasticity of Invasive Edge Glioma Stem-like Cells in Response to Ionizing Radiation.

Minata M, Audia A, Shi J, Lu S, Bernstock J, Pavlyukov MS, Das A, Kim SH, Shin YJ, Lee Y, Koo H, Snigdha K, Waghmare I, Guo X, Mohyeldin A, Gallego-Perez D, Wang J, Chen D, Cheng P, Mukheef F, Contreras M, Reyes JF, Vaillant B, Sulman EP, Cheng SY, Markert JM, Tannous BA, Lu X, Kango-Singh M, Lee LJ, Nam DH, Nakano I, Bhat KP.

Cell Rep. 2019 Feb 12;26(7):1893-1905.e7. doi: 10.1016/j.celrep.2019.01.076.

4.

The molecular landscape of glioma in patients with Neurofibromatosis 1.

D'Angelo F, Ceccarelli M, Tala, Garofano L, Zhang J, Frattini V, Caruso FP, Lewis G, Alfaro KD, Bauchet L, Berzero G, Cachia D, Cangiano M, Capelle L, de Groot J, DiMeco F, Ducray F, Farah W, Finocchiaro G, Goutagny S, Kamiya-Matsuoka C, Lavarino C, Loiseau H, Lorgis V, Marras CE, McCutcheon I, Nam DH, Ronchi S, Saletti V, Seizeur R, Slopis J, Suñol M, Vandenbos F, Varlet P, Vidaud D, Watts C, Tabar V, Reuss DE, Kim SK, Meyronet D, Mokhtari K, Salvador H, Bhat KP, Eoli M, Sanson M, Lasorella A, Iavarone A.

Nat Med. 2019 Jan;25(1):176-187. doi: 10.1038/s41591-018-0263-8. Epub 2018 Dec 10.

5.

RADX Modulates RAD51 Activity to Control Replication Fork Protection.

Bhat KP, Krishnamoorthy A, Dungrawala H, Garcin EB, Modesti M, Cortez D.

Cell Rep. 2018 Jul 17;24(3):538-545. doi: 10.1016/j.celrep.2018.06.061.

6.

RPA and RAD51: fork reversal, fork protection, and genome stability.

Bhat KP, Cortez D.

Nat Struct Mol Biol. 2018 Jun;25(6):446-453. doi: 10.1038/s41594-018-0075-z. Epub 2018 May 28. Review.

7.

IL-8 associates with a pro-angiogenic and mesenchymal subtype in glioblastoma.

Conroy S, Kruyt FAE, Wagemakers M, Bhat KPL, den Dunnen WFA.

Oncotarget. 2018 Feb 28;9(21):15721-15731. doi: 10.18632/oncotarget.24595. eCollection 2018 Mar 20.

8.

Ritanserin, a novel agent targeting the mesenchymal subtype of glioblastomas.

Audia A, Bhat KP.

Neuro Oncol. 2018 Jan 22;20(2):151-152. doi: 10.1093/neuonc/nox240. No abstract available.

9.

Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo.

Boyd NH, Walker K, Fried J, Hackney JR, McDonald PC, Benavides GA, Spina R, Audia A, Scott SE, Libby CJ, Tran AN, Bevensee MO, Griguer C, Nozell S, Gillespie GY, Nabors B, Bhat KP, Bar EE, Darley-Usmar V, Xu B, Gordon E, Cooper SJ, Dedhar S, Hjelmeland AB.

JCI Insight. 2017 Dec 21;2(24). pii: 92928. doi: 10.1172/jci.insight.92928.

10.

GPR56/ADGRG1 Inhibits Mesenchymal Differentiation and Radioresistance in Glioblastoma.

Moreno M, Pedrosa L, Paré L, Pineda E, Bejarano L, Martínez J, Balasubramaniyan V, Ezhilarasan R, Kallarackal N, Kim SH, Wang J, Audia A, Conroy S, Marin M, Ribalta T, Pujol T, Herreros A, Tortosa A, Mira H, Alonso MM, Gómez-Manzano C, Graus F, Sulman EP, Piao X, Nakano I, Prat A, Bhat KP, de la Iglesia N.

Cell Rep. 2017 Nov 21;21(8):2183-2197. doi: 10.1016/j.celrep.2017.10.083.

11.

A relative increase in circulating platelets following chemoradiation predicts for poor survival of patients with glioblastoma.

Boonyawan K, Hess KR, Yang J, Long L, Wang Q, Ezhilarasan R, Auia A, Alfaro-Munoz KD, de Groot JF, Bhat KP, Sulman EP.

Oncotarget. 2017 Oct 12;8(52):90488-90495. doi: 10.18632/oncotarget.21799. eCollection 2017 Oct 27.

12.

CDK4/6 inhibition is more active against the glioblastoma proneural subtype.

Li M, Xiao A, Floyd D, Olmez I, Lee J, Godlewski J, Bronisz A, Bhat KPL, Sulman EP, Nakano I, Purow B.

Oncotarget. 2017 Jul 21;8(33):55319-55331. doi: 10.18632/oncotarget.19429. eCollection 2017 Aug 15.

13.

Targeting MIR155HG in glioma: a novel approach.

Balasubramaniyan V, Bhat KP.

Neuro Oncol. 2017 Sep 1;19(9):1152-1153. doi: 10.1093/neuonc/nox095. No abstract available.

14.

The Impact of the Tumor Microenvironment on the Properties of Glioma Stem-Like Cells.

Audia A, Conroy S, Glass R, Bhat KPL.

Front Oncol. 2017 Jul 10;7:143. doi: 10.3389/fonc.2017.00143. eCollection 2017. Review.

15.

RADX Promotes Genome Stability and Modulates Chemosensitivity by Regulating RAD51 at Replication Forks.

Dungrawala H, Bhat KP, Le Meur R, Chazin WJ, Ding X, Sharan SK, Wessel SR, Sathe AA, Zhao R, Cortez D.

Mol Cell. 2017 Aug 3;67(3):374-386.e5. doi: 10.1016/j.molcel.2017.06.023. Epub 2017 Jul 20.

16.

FOXD1-ALDH1A3 Signaling Is a Determinant for the Self-Renewal and Tumorigenicity of Mesenchymal Glioma Stem Cells.

Cheng P, Wang J, Waghmare I, Sartini S, Coviello V, Zhang Z, Kim SH, Mohyeldin A, Pavlyukov MS, Minata M, Valentim CL, Chhipa RR, Bhat KP, Dasgupta B, La Motta C, Kango-Singh M, Nakano I.

Cancer Res. 2016 Dec 15;76(24):7219-7230. Epub 2016 Aug 28.

17.

Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype.

Gabrusiewicz K, Rodriguez B, Wei J, Hashimoto Y, Healy LM, Maiti SN, Thomas G, Zhou S, Wang Q, Elakkad A, Liebelt BD, Yaghi NK, Ezhilarasan R, Huang N, Weinberg JS, Prabhu SS, Rao G, Sawaya R, Langford LA, Bruner JM, Fuller GN, Bar-Or A, Li W, Colen RR, Curran MA, Bhat KP, Antel JP, Cooper LJ, Sulman EP, Heimberger AB.

JCI Insight. 2016;1(2). pii: 85841. doi: 10.1172/jci.insight.85841. Epub 2016 Feb 25.

18.

Serine/Threonine Kinase MLK4 Determines Mesenchymal Identity in Glioma Stem Cells in an NF-κB-dependent Manner.

Kim SH, Ezhilarasan R, Phillips E, Gallego-Perez D, Sparks A, Taylor D, Ladner K, Furuta T, Sabit H, Chhipa R, Cho JH, Mohyeldin A, Beck S, Kurozumi K, Kuroiwa T, Iwata R, Asai A, Kim J, Sulman EP, Cheng SY, Lee LJ, Nakada M, Guttridge D, DasGupta B, Goidts V, Bhat KP, Nakano I.

Cancer Cell. 2016 Feb 8;29(2):201-13. doi: 10.1016/j.ccell.2016.01.005.

19.

Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact.

Sathyan P, Zinn PO, Marisetty AL, Liu B, Kamal MM, Singh SK, Bady P, Lu L, Wani KM, Veo BL, Gumin J, Kassem DH, Robinson F, Weng C, Baladandayuthapani V, Suki D, Colman H, Bhat KP, Sulman EP, Aldape K, Colen RR, Verhaak RG, Lu Z, Fuller GN, Huang S, Lang FF, Sawaya R, Hegi M, Majumder S.

J Neurosci. 2015 Nov 11;35(45):15097-112. doi: 10.1523/JNEUROSCI.1265-15.2015.

20.

The Replication Checkpoint Prevents Two Types of Fork Collapse without Regulating Replisome Stability.

Dungrawala H, Rose KL, Bhat KP, Mohni KN, Glick GG, Couch FB, Cortez D.

Mol Cell. 2015 Sep 17;59(6):998-1010. doi: 10.1016/j.molcel.2015.07.030. Epub 2015 Sep 10.

21.

Aberrant mesenchymal differentiation of glioma stem-like cells: implications for therapeutic targeting.

Balasubramaniyan V, Vaillant B, Wang S, Gumin J, Butalid ME, Sai K, Mukheef F, Kim SH, Boddeke HW, Lang F, Aldape K, Sulman EP, Bhat KP, Colman H.

Oncotarget. 2015 Oct 13;6(31):31007-17. doi: 10.18632/oncotarget.5219.

22.

EZH2 protects glioma stem cells from radiation-induced cell death in a MELK/FOXM1-dependent manner.

Kim SH, Joshi K, Ezhilarasan R, Myers TR, Siu J, Gu C, Nakano-Okuno M, Taylor D, Minata M, Sulman EP, Lee J, Bhat KP, Salcini AE, Nakano I.

Stem Cell Reports. 2015 Feb 10;4(2):226-38. doi: 10.1016/j.stemcr.2014.12.006. Epub 2015 Jan 15.

23.

High-affinity DNA-binding domains of replication protein A (RPA) direct SMARCAL1-dependent replication fork remodeling.

Bhat KP, Bétous R, Cortez D.

J Biol Chem. 2015 Feb 13;290(7):4110-7. doi: 10.1074/jbc.M114.627083. Epub 2014 Dec 31.

24.

Subclassification of newly diagnosed glioblastomas through an immunohistochemical approach.

Conroy S, Kruyt FA, Joseph JV, Balasubramaniyan V, Bhat KP, Wagemakers M, Enting RH, Walenkamp AM, den Dunnen WF.

PLoS One. 2014 Dec 29;9(12):e115687. doi: 10.1371/journal.pone.0115687. eCollection 2014.

25.

Differential ubiquitination and degradation of huntingtin fragments modulated by ubiquitin-protein ligase E3A.

Bhat KP, Yan S, Wang CE, Li S, Li XJ.

Proc Natl Acad Sci U S A. 2014 Apr 15;111(15):5706-11. doi: 10.1073/pnas.1402215111. Epub 2014 Mar 31.

26.

EGFR and EGFRvIII in glioblastoma: partners in crime.

Zadeh G, Bhat KP, Aldape K.

Cancer Cell. 2013 Oct 14;24(4):403-4. doi: 10.1016/j.ccr.2013.09.017.

27.

Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma.

Bhat KPL, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, Wani K, Heathcock L, James JD, Goodman LD, Conroy S, Long L, Lelic N, Wang S, Gumin J, Raj D, Kodama Y, Raghunathan A, Olar A, Joshi K, Pelloski CE, Heimberger A, Kim SH, Cahill DP, Rao G, Den Dunnen WFA, Boddeke HWGM, Phillips HS, Nakano I, Lang FF, Colman H, Sulman EP, Aldape K.

Cancer Cell. 2013 Sep 9;24(3):331-46. doi: 10.1016/j.ccr.2013.08.001. Epub 2013 Aug 29.

28.

Not expecting the unexpected: diacylglycerol kinase alpha as a cancer target.

Bhat KP, Aldape K.

Cancer Discov. 2013 Jul;3(7):726-7. doi: 10.1158/2159-8290.CD-13-0244.

29.

Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma.

Doucette TA, Kong LY, Yang Y, Ferguson SD, Yang J, Wei J, Qiao W, Fuller GN, Bhat KP, Aldape K, Priebe W, Bögler O, Heimberger AB, Rao G.

Neuro Oncol. 2012 Sep;14(9):1136-45. doi: 10.1093/neuonc/nos139. Epub 2012 Jun 29.

30.

The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma.

Bhat KP, Salazar KL, Balasubramaniyan V, Wani K, Heathcock L, Hollingsworth F, James JD, Gumin J, Diefes KL, Kim SH, Turski A, Azodi Y, Yang Y, Doucette T, Colman H, Sulman EP, Lang FF, Rao G, Copray S, Vaillant BD, Aldape KD.

Genes Dev. 2011 Dec 15;25(24):2594-609. doi: 10.1101/gad.176800.111.

31.

Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors.

Singh MM, Manton CA, Bhat KP, Tsai WW, Aldape K, Barton MC, Chandra J.

Neuro Oncol. 2011 Aug;13(8):894-903. doi: 10.1093/neuonc/nor049. Epub 2011 Jun 8.

32.

Caspase-3 cleavage links delta-catenin to the novel nuclear protein ZIFCAT.

Gu D, Tonthat NK, Lee M, Ji H, Bhat KP, Hollingsworth F, Aldape KD, Schumacher MA, Zwaka TP, McCrea PD.

J Biol Chem. 2011 Jul 1;286(26):23178-88. doi: 10.1074/jbc.M110.167544. Epub 2011 May 11.

33.

Proteolytic and non-proteolytic roles of ubiquitin and the ubiquitin proteasome system in transcriptional regulation.

Bhat KP, Greer SF.

Biochim Biophys Acta. 2011 Feb;1809(2):150-5. doi: 10.1016/j.bbagrm.2010.11.006. Epub 2010 Dec 22. Review.

PMID:
21184853
34.
35.

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.

Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, Wilson RK, Van Den Berg D, Shen H, Bengtsson H, Neuvial P, Cope LM, Buckley J, Herman JG, Baylin SB, Laird PW, Aldape K; Cancer Genome Atlas Research Network.

Cancer Cell. 2010 May 18;17(5):510-22. doi: 10.1016/j.ccr.2010.03.017. Epub 2010 Apr 15.

36.

Association of the 19S proteasomal ATPases with the ATPase-binding domain of CIITA is essential for CIITA stability and MHC class II expression.

Bhat KP, Truax AD, Brooks JK, Greer SF.

Immunol Cell Biol. 2010 Nov-Dec;88(8):807-16. doi: 10.1038/icb.2010.45. Epub 2010 Mar 30.

PMID:
20351748
37.

Tie2-mediated multidrug resistance in malignant gliomas is associated with upregulation of ABC transporters.

Martin V, Xu J, Pabbisetty SK, Alonso MM, Liu D, Lee OH, Gumin J, Bhat KP, Colman H, Lang FF, Fueyo J, Gomez-Manzano C.

Oncogene. 2009 Jun 18;28(24):2358-63. doi: 10.1038/onc.2009.103. Epub 2009 May 4.

38.

Selective repression of YKL-40 by NF-kappaB in glioma cell lines involves recruitment of histone deacetylase-1 and -2.

Bhat KP, Pelloski CE, Zhang Y, Kim SH, deLaCruz C, Rehli M, Aldape KD.

FEBS Lett. 2008 Sep 22;582(21-22):3193-200. doi: 10.1016/j.febslet.2008.08.010. Epub 2008 Aug 15.

39.

Regulation of acetylation at the major histocompatibility complex class II proximal promoter by the 19S proteasomal ATPase Sug1.

Koues OI, Dudley RK, Truax AD, Gerhardt D, Bhat KP, McNeal S, Greer SF.

Mol Cell Biol. 2008 Oct;28(19):5837-50. doi: 10.1128/MCB.00535-08. Epub 2008 Jul 28.

40.

The 19S proteasome ATPase Sug1 plays a critical role in regulating MHC class II transcription.

Bhat KP, Turner JD, Myers SE, Cape AD, Ting JP, Greer SF.

Mol Immunol. 2008 Apr;45(8):2214-24. doi: 10.1016/j.molimm.2007.12.001. Epub 2008 Jan 22.

PMID:
18215421
41.

Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation.

Itahana K, Mao H, Jin A, Itahana Y, Clegg HV, Lindström MS, Bhat KP, Godfrey VL, Evan GI, Zhang Y.

Cancer Cell. 2007 Oct;12(4):355-66.

42.

PTEN down regulates AP-1 and targets c-fos in human glioma cells via PI3-kinase/Akt pathway.

Koul D, Shen R, Shishodia S, Takada Y, Bhat KP, Reddy SA, Aggarwal BB, Yung WK.

Mol Cell Biochem. 2007 Jun;300(1-2):77-87. Epub 2007 Jan 18.

PMID:
17235455
43.

Biomechanics and analysis of running gait.

Dugan SA, Bhat KP.

Phys Med Rehabil Clin N Am. 2005 Aug;16(3):603-21. Review.

PMID:
16005396
44.

Essential role of ribosomal protein L11 in mediating growth inhibition-induced p53 activation.

Bhat KP, Itahana K, Jin A, Zhang Y.

EMBO J. 2004 Jun 16;23(12):2402-12. Epub 2004 May 20.

45.

Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation.

Itahana K, Bhat KP, Jin A, Itahana Y, Hawke D, Kobayashi R, Zhang Y.

Mol Cell. 2003 Nov;12(5):1151-64.

46.

Cancer chemopreventive activity of resveratrol.

Bhat KP, Pezzuto JM.

Ann N Y Acad Sci. 2002 May;957:210-29. Review.

PMID:
12074974
47.

Biological effects of resveratrol.

Bhat KPL, Kosmeder JW 2nd, Pezzuto JM.

Antioxid Redox Signal. 2001 Dec;3(6):1041-64. Review.

PMID:
11813979
48.

Natural modulators of estrogen biosynthesis and function as chemopreventive agents.

Bhat KP, Pezzuto JM.

Arch Pharm Res. 2001 Dec;24(6):473-84. Review.

PMID:
11794520
49.

Trifolium pratense (red clover) exhibits estrogenic effects in vivo in ovariectomized Sprague-Dawley rats.

Burdette JE, Liu J, Lantvit D, Lim E, Booth N, Bhat KP, Hedayat S, Van Breemen RB, Constantinou AI, Pezzuto JM, Farnsworth NR, Bolton JL.

J Nutr. 2002 Jan;132(1):27-30.

PMID:
11773503
50.

Aromatase inhibitors from Broussonetia papyrifera.

Lee D, Bhat KP, Fong HH, Farnsworth NR, Pezzuto JM, Kinghorn AD.

J Nat Prod. 2001 Oct;64(10):1286-93.

PMID:
11678652

Supplemental Content

Support Center